A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Sponsor: Aeglea Biotherapeutics
This PHASE2 trial investigates Acute Myeloid Leukemia and Myelodysplastic Syndrome and is currently completed. Aeglea Biotherapeutics leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
Phase: PHASE1 → PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aeglea Biotherapeutics
For direct contact, visit the study record on ClinicalTrials.gov .